1. "Gynecologic Medicine Service"
Formats
  1. Journal Article (1087)
  2. Meeting Abstract (890)
  3. Review (52)
  4. Book Section (46)
  5. Editorial (35)
  6. Guidelines (21)
  7. Correspondence (9)
  8. Miscellaneous (3)
  9. Research Letter (2)
  10. Book Whole (1)
Groups
  1. Gynecologic Medicine Service (2146)
  2. Solid Tumor Oncology Division (2146)
  3. Department of Medicine (2142)
  4. Gynecology Disease Management Team (1846)
  5. GDMT, Medicine (1828)
  6. Surgery (594)

More Groups

People
  1. Carol Aghajanian (607)
  2. Martee Hensley (289)
  3. Nadeem Abu-Rustum (288)
  4. Roisin O'Cearbhaill (271)
  5. Vicky Makker (263)
  6. Paul Sabbatini (262)

More People

Years
  1. 2025 (41)
  2. 2024 (167)
  3. 2023 (171)
  4. 2022 (209)
  5. 2021 (163)
  6. 2020 (203)

More Years

Publications
  1. Journal of Clinical Oncology (450)
  2. Gynecologic Oncology (418)
  3. International Journal of Gynecological Cancer (154)
  4. Annals of Oncology (116)
  5. Clinical Cancer Research (67)
  6. Cancer Research (55)

More Publications

Publishers
  1. Elsevier Inc. (542)
  2. American Society of Clinical Oncology (489)
  3. Lippincott Williams & Wilkins (181)
  4. American Association for Cancer Research (168)
  5. Oxford University Press (143)
  6. Nature Publishing Group (86)

More Publishers

Results (2146)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: Efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the phase III SOLO1 trial
    Meeting Abstract

    Moore, K.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: An analysis from the phase 3 study ARIEL3
    Meeting Abstract

    Clamp, A. R.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Scambia, G.; Leary, A.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: Post hoc exploratory analyses by BRCA mutation status and patient age
    Meeting Abstract

    Colombo, N.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; Leary, A.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Niraparib therapy in patients with newly diagnosed advanced ovarian cancer after chemotherapy: PRIMA/ENGOT-OV26/GOG-3012 study
    Meeting Abstract

    Gonzalez-Martin, A.; Pothuri, B.; Vergote, I.; Christensen, R. D.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers
    Meeting Abstract

    Schram, A. M.; O'Reilly, E. M.; Somwar, R.; Benayed, R.; Shameem, S.; Chauhan, T.; Torrisi, J.; Ford, J.; Maussang, D.; Wasserman, E.; more...
    Molecular Cancer Therapeutics (2019)

    Fulltext@MSK | Save
  • Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
    Meeting Abstract

    Friedlander, M. L.; Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer
    Journal Article

    Coleman, R. L.; Fleming, G. F.; Brady, M. F.; Swisher, E. M.; Steffensen, K. D.; Friedlander, M.; Okamoto, A.; Moore, K. N.; Ben-Baruch, N. E.; Werner, T. L.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Niraparib in patients with newly diagnosed advanced ovarian cancer
    Journal Article

    Gonzalez-Martin, A.; Pothuri, B.; Vergote, I.; Christensen, R. D.; Graybill, W.; Mirza, M. R.; McCormick, C.; Lorusso, D.; Hoskins, P.; Freyer, G.; more...
    New England Journal of Medicine (2019)

    Fulltext@MSK | Save
  • Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study
    Journal Article

    Westin, S. N.; Sill, M. W.; Coleman, R. L.; Waggoner, S.; Moore, K. N.; Mathews, C. A.; Martin, L. P.; Modesitt, S. C.; Lee, S.; Ju, Z.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
    Journal Article

    O'Cearbhaill, R. E.; Deng, W.; Chen, L. M.; Lucci, J. A. 3rd; Behbakht, K.; Spirtos, N. M.; Muller, C. Y.; Benigno, B. B.; Powell, M. A.; Berry, E.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save